ClinicalTrials.gg
RecruitingNCT04613570SUPREMEUpdated Mar 31, 2022

SUrveillance of PREMalignant Stomach - Individualized Endoscopic Follow-up

An interventional study of Upper gastrointestinal endoscopy in Atrophic Gastritis, Intestinal Metaplasia and Gastric Dysplasia, sponsored by Instituto Portugues de Oncologia, Francisco Gentil, Porto. Recruiting at 1 site in Portugal. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2022-03-31.

Sponsored by Instituto Portugues de Oncologia, Francisco Gentil, Porto · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jan 2021; still recruiting 5 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
912
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Study summary

Introduction: Gastric atrophy and intestinal metaplasia are the principal precursors for gastric cancer and, therefore, are considered gastric premalignant conditions. Although current guidelines recommend surveillance of individuals with these conditions, the best method for its identification and staging (histological vs endoscopy) and the best time schedule for follow-up are still controversial. Aims: To describe for the first-time patients with premalignant conditions both clinically (familial history), histologically (OLGA/OLGIM; complete/incomplete metaplasia) and endoscopically (EGGIM) using validated scales and to describe evolution of these parameters through time. To estimate prospectively the gastric cancer risk according to EGGIM stages. To define the best endoscopic surveillance follow-up for the several stages considering clinical, histological and endoscopic factors.

Methods: Multicenter study involving different gastroenterology departments from several countries. Consecutive patients older than 45 years scheduled for upper endoscopy in each of these centers will be evaluated by High-Resolution- endoscopy with virtual chromoendoscopy and EGGIM will be calculated. Guided biopsies (if areas suspicious of IM) and/or random biopsies (if no areas suspicious of IM) in antrum and corpus will be made and OLGA/OLGIM stages calculated. Patients will be evaluated in clinical consultation and database will be fulfilled. All patients will be eradicated for Helicobacter pylori infection if positive. At that occasion, all the patients with EGGIM>5 and/or OLGA III/IV and/or OLGIM III/IV will be randomized for yearly (12 to 16 months) or every three years (32-40 months) endoscopic follow-up during a period of 6 years (SUPREME I). Endoscopic observational follow-up will be scheduled for patients with EGGIM 1-4 and OLGIM I/II at 3 and 6 years (SUPREME II). For individuals with no evidence of IM (EGGIM 0 and OLGIM 0, OLGA 0-II) a follow-up endoscopy 6 years after will be proposed (SUPREME III).

Read the detailed description

Introduction: Gastric atrophy and intestinal metaplasia are the principal precursors for gastric cancer and, therefore, are considered gastric premalignant conditions. Although current guidelines recommend surveillance of individuals with these conditions, the best method for its identification and staging (histological vs endoscopy) and the best time schedule for follow-up are still controversial. Aims: To describe for the first-time patients with premalignant conditions both clinically (familial history), histologically (OLGA/OLGIM; complete/incomplete metaplasia) and endoscopically (EGGIM) using validated scales and to describe evolution of these parameters through time. To estimate prospectively the gastric cancer risk according to EGGIM stages. To define the best endoscopic surveillance follow-up for the several stages considering clinical, histological and endoscopic factors.

Methods: Multicenter study involving different gastroenterology departments from several countries. Consecutive patients older than 45 years scheduled for upper endoscopy in each of these centers will be evaluated by High-Resolution-endoscopy with virtual chromoendoscopy and EGGIM will be calculated. Guided biopsies (if areas suspicious of IM) and/or random biopsies (if no areas suspicious of IM) in antrum and corpus will be made and OLGA/OLGIM stages calculated. Patients will be evaluated in clinical consultation and database will be fulfilled. All patients will be eradicated for Helicobacter pylori infection if positive. At that occasion, all the patients with EGGIM>5 and/or OLGA III/IV and/or OLGIM III/IV will be randomized for yearly (12 to 16 months) or every three years (32-40 months) endoscopic follow-up during a period of 6 years (SUPREME I). Endoscopic observational follow-up will be scheduled for patients with EGGIM 1-4 and OLGIM I/II at 3 and 6 years (SUPREME II). For individuals with no evidence of IM (EGGIM 0 and OLGIM 0, OLGA 0-II) a follow-up endoscopy 6 years after will be proposed (SUPREME III).

02

Conditions studied

  • Atrophic Gastritis
  • Intestinal Metaplasia
  • Gastric Dysplasia
  • Gastric Cancer

Keywords

  • atrophic gastritis
  • gastric cancer
  • intestinal metaplasia
  • gastric dysplasia
  • surveillance
03

In context

Gastritis, Atrophic

77 studies on the registry are indexed under Gastritis, Atrophic; 38 are open to participants now.

This study's planned enrollment of 912 is above the median of 91 across 21 interventional studies indexed under Gastritis, Atrophic.

Browse Gastritis, Atrophic studies →

Lead sponsor

Instituto Portugues de Oncologia, Francisco Gentil, Porto is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for upper GI endoscopy with indication for gastric , including those with known gastric pathology (e.g. auto-immune gastritis) or premalignant conditions (e.g patients under surveillance because of atrophic gastritis);
  • Age above 45 years old

Exclusion criteria

Exclusion Criteria:

  • History of previous gastrectomy;
  • History of endoscopic resection of neoplastic lesion
  • History of previous gastric dysplasia (even with no detectable lesion)
  • Hereditary syndromes that increase gastric cancer risk (familial adenomatous polyposis; Lynch syndrome)
  • Serious comorbidities (ASA 3 or more)
  • Medication with anticoagulants
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
912 participants (estimated)

Study arms

  • Experimental
    Yearly endoscopy

    Upper gastrointestinal endoscopy every year (12-16 months)

    Diagnostic Test: Upper gastrointestinal endoscopy

  • Other
    Endoscopy every 3 years

    Upper gastrointestinal endoscopy every three years (32-40 months)

    Diagnostic Test: Upper gastrointestinal endoscopy

Interventions

  • Diagnostic testUpper gastrointestinal endoscopy

    In all patient's complete gastroscopy first with White light and then with virtual chromoendoscopy will be made; * Suspicious lesions with dysplasia/cancer will be biopsied 1-2 fragments in a different vial; if an irregular area of mucosa (pattern C) with no clearly defined lesion then 1-2 guided biopsies fragments will be taken and sent in a different vial; * EGGIM (Endoscopic Grading of Gastric Intestinal Metaplasia) will be calculated according to previous description of this classification: * If EGGIM 0 (no endoscopically apparent IM) biopsies will be made in antrum, incisura and corpus according to Sydney-Houston protocol; * If EGGIM 1 or more guided biopsies of suspicious areas of IM should be made replacing the random biopsies in that particular area; * Antrum, incisura and corpus fragments should be sent in 3 separate vials;

06

What researchers measure

Primary outcomes

  1. Dysplasia

    Proportion of patients with dysplasia (low or high-grade)

    Time frame: 6 years

  2. Carcinoma

    Proportion of patients with gastric adenocarcinoma

    Time frame: 6 years

Secondary outcomes

  1. Curative criteria

    Proportion of patients with intramucosal carcinoma with low-risk criteria ("curative" criteria)

    Time frame: 6 years

  2. Non-curative criteria

    Proportion of patients with submucosal, diffuse type or intramucosal carcinoma with high-risk criteria ("non-curative" criteria)

    Time frame: 6 years

  3. Advanced gastric cancer

    Proportion of patients with advanced gastric cancer (without indication for endoscopic treatment)

    Time frame: 6 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2021 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2020
First posted
Nov 3, 2020
StartActual
Jan 2, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04613570
Lead sponsor
Instituto Portugues de Oncologia, Francisco Gentil, Porto
Responsible party
Diogo Libânio (Principal Investigator, Instituto Portugues de Oncologia, Francisco Gentil, Porto) — Principal investigator
First posted
Nov 3, 2020
Start date
Jan 2, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 31, 2022

Study contacts

Pedro Pimentel-Nunes, MD PhD
Contact
pedro.nunes@ipoporto.min-saude.pt
+35122508400 ext. 3348
Diogo Libanio, MD PhD
Contact
diogo.monteiro@ipoporto.min-saude.pt
+35122508400 ext. 7442
Pedro Pimentel-Nunes, MD PhD
principal investigator · Instituto Português de Oncologia do Porto, Francisco Gentil

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion